Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Initiated Vasopressor Therapy vs. Standard Fluid Therapy in Hypotensive Emergency Department Patients (VASOSHOCK)
2023-504584-16-00Phase 3Authorised
- Sponsor
- University Hospital Odense
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised trial of norepinephrine in hypotension and Shock (2 arms), sponsored by University Hospital Odense. Primary endpoint: Proportion achieving target blood pressure at 90 (±15) minutes. Planned start Dec 2023; status: authorised.
02
Drugs
norepinephrine
03
Conditions
hypotensionShock
Beyond the preview
Go deeper on 2023-504584-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504584-16-00.